1 out of 36 men will die of prostate cancer. Get involved.
The Massachusetts Prostate Cancer Coalition (MPCC) educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer. More information can be found here.
Our Vision: Educate | Inform | Advocate
Five Facts about Prostate Cancer
1PrevalenceProstate cancer is the most common (non-skin) cancer in American men.
2Prostate cancer effects 1 in 7 men.1 in 7 men will be diagnosed with prostate cancer during their lifetime. This year in Massachusetts another 4,762 new cases will be diagnosed.
3Second leading cause of cancer death in men.Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. In Massachusetts, 614 men will die from prostate cancer this year.
4Prostate cancer top risk factors.
African-American men are twice as likely to die of prostate cancer as white men. Asian-Americans and Hispanic/Latinos have lower rates of prostate cancer than non-Hispanic white men.
Prostate cancer occurs mainly in older men. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66.
5This year 27,540 men will die of prostate cancer.
Yet, most men diagnosed with prostate cancer will not die from it. In fact, more than 2.9 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.
Statistics from The American Cancer Society 2015
We need your support! Become a Member or Donate to MPCC today.
One in seven men will be diagnosed with prostate cancer this year. It’s the second leading cause of cancer-related death among men. There is a new campaign teaming the NFL and Urology Foundation to help men know their stats. Read more read more →
Last week, the FDA gave breakthrough status to a drug, Lynparza (olaparib, AstraZeneca), for treating some forms of metastatic prostate cancer. This means the agency will expedite review and possible approval of this new kind of therapy, a PARP inhibitor for men with advanced, refractory prostate cancer. Read more read more →